search
Back to results

The Sun Protective Effect of Melatonin

Primary Purpose

Sunburn

Status
Completed
Phase
Phase 1
Locations
Denmark
Study Type
Interventional
Intervention
Melatonin
Sponsored by
Herlev Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Sunburn focused on measuring Melatonin, Sunburn, Erythema, Sunlight, Ultraviolet rays

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy volunteers of both sexes.
  • Skin type 1-3 according to Fitzpatrick skin type scale.
  • No sun exposure on skin area tested in the study 4 weeks prior to the study.

Exclusion Criteria:

  • Active skin disease
  • Participant that do not react to the given sun exposure with a change in a-value >5 are excluded from the data.
  • Pregnancy
  • Previous malignant or pre malignant skin disease.

Sites / Locations

  • Gastroenheden, Herlev Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Active Comparator

Active Comparator

Active Comparator

Placebo Comparator

No Intervention

Arm Label

Melatonin: Melatonin cream 2,5%

Melatonin: Melatonin cream 0,5%

Melatonin: Melatonin cream 12,5%

placebo cream

No treatment

Arm Description

One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied

One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied.

One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied.

One square on the back of each volunteers will be randomized to have placebo cream (vehicle) applied.

One square on the back of each volunteers will be randomized to receive no treatment.

Outcomes

Primary Outcome Measures

Reduction of erythema assessed by digital image analysis (Image J) after treatment with melatonin/placebo before sun exposure.
The alpha value measured in a "color space converted" image will represent the degree of erythema

Secondary Outcome Measures

Testing for primary hyperalgesia in the sun exposed area with Pin-Prick monofilaments. Testing for primary hyperalgesia in the sun-exposed area with Pin-Prick monofilaments.

Full Information

First Posted
June 6, 2013
Last Updated
August 28, 2013
Sponsor
Herlev Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01873430
Brief Title
The Sun Protective Effect of Melatonin
Official Title
The Sun Protective Effect of Melatonin: a Randomized, Placebo-controlled, Double-blind Study on Healthy Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
August 2013
Overall Recruitment Status
Completed
Study Start Date
May 2013 (undefined)
Primary Completion Date
May 2013 (Actual)
Study Completion Date
August 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Herlev Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of this study is to investigate the sun protective effect of melatonin, when used as a cream applied before sun exposure. Sun exposure induces erythema as indication of an inflammatory reaction in the skin. It is proven that the amount of free radicals in the skin are increased by UV exposure. Furthermore, it is known that melatonin is a potent antioxidant. It is hypothesized that melatonin can be protective against the UV induced release of free radicals by acting as a radical scavenger and thereby protect against UV-induced cellular damage.
Detailed Description
This study investigates the sun protective effect of melatonin when used as a creme applied before sun exposure. The study is a randomized, placebo-controlled, double-blinded study conducted on healthy volunteers. The volunteers will have 5 squares of 8 cm*8 cm on their backs, which each will be randomized to receive one of following: melatonin cream 0,5%; melatonin cream 2,5%; melatonin cream 12,5%; placebo cream (vehicle) and no treatment. After randomization and received treatment the volunteers will be exposed to strong midday sun (UV-index of approximately 9) for 40 minutes. The outcomes parameters (degree of erythema and pain sensation) are measured at baseline and 1,4,8 and 24 hours post exposure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sunburn
Keywords
Melatonin, Sunburn, Erythema, Sunlight, Ultraviolet rays

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
22 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Melatonin: Melatonin cream 2,5%
Arm Type
Active Comparator
Arm Description
One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied
Arm Title
Melatonin: Melatonin cream 0,5%
Arm Type
Active Comparator
Arm Description
One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied.
Arm Title
Melatonin: Melatonin cream 12,5%
Arm Type
Active Comparator
Arm Description
One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied.
Arm Title
placebo cream
Arm Type
Placebo Comparator
Arm Description
One square on the back of each volunteers will be randomized to have placebo cream (vehicle) applied.
Arm Title
No treatment
Arm Type
No Intervention
Arm Description
One square on the back of each volunteers will be randomized to receive no treatment.
Intervention Type
Drug
Intervention Name(s)
Melatonin
Primary Outcome Measure Information:
Title
Reduction of erythema assessed by digital image analysis (Image J) after treatment with melatonin/placebo before sun exposure.
Description
The alpha value measured in a "color space converted" image will represent the degree of erythema
Time Frame
Primary outcome is assessed at: baseline and 1,4,8 and 24 hours post exposure
Secondary Outcome Measure Information:
Title
Testing for primary hyperalgesia in the sun exposed area with Pin-Prick monofilaments. Testing for primary hyperalgesia in the sun-exposed area with Pin-Prick monofilaments.
Time Frame
The secondary outcome is assessed at: baseline and 1,4,8 and 24 hours post exposure.
Other Pre-specified Outcome Measures:
Title
Visual inspection of erythema using Frosch-Klingman scale.
Time Frame
This secondary outcome is assessed at: baseline and 1,4,8 and 24 hours post exposure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy volunteers of both sexes. Skin type 1-3 according to Fitzpatrick skin type scale. No sun exposure on skin area tested in the study 4 weeks prior to the study. Exclusion Criteria: Active skin disease Participant that do not react to the given sun exposure with a change in a-value >5 are excluded from the data. Pregnancy Previous malignant or pre malignant skin disease.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cecilie Scheuer, Research Scholar
Organizational Affiliation
Gastroenheden, Herlev Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Gastroenheden, Herlev Hospital
City
Herlev
ZIP/Postal Code
2730
Country
Denmark

12. IPD Sharing Statement

Learn more about this trial

The Sun Protective Effect of Melatonin

We'll reach out to this number within 24 hrs